Loring Wolcott & Coolidge Fiduciary Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.37M Sell
56,816
-4,395
-7% -$115K 0.01% 150
2026
Q1
$1.65M Sell
61,211
-2,891
-5% -$77K 0.02% 131
2025
Q4
$1.7M Sell
64,102
-31,348
-33% -$791K 0.02% 136
2025
Q3
$2.35M Sell
95,450
-3,160
-3% -$78K 0.02% 116
2025
Q2
$2.39M Sell
98,610
-2,363
-2% -$55.1K 0.02% 119
2025
Q1
$2.26M Sell
100,973
-1,116
-1% -$29.2K 0.02% 122
2024
Q4
$2.74M Sell
102,089
-1,226
-1% -$33.3K 0.02% 123
2024
Q3
$2.96M Sell
103,315
-1,582
-2% -$46.1K 0.03% 119
2024
Q2
$3.09M Buy
104,897
+31,595
+43% +$870K 0.03% 100
2024
Q1
$1.92M Sell
73,302
-1,050
-1% -$29.1K 0.02% 117
2023
Q4
$2.01M Sell
74,352
-1,500
-2% -$45.3K 0.02% 117
2023
Q3
$2.31M Sell
75,852
-2,455
-3% -$86.8K 0.03% 106
2023
Q2
$2.87M Sell
78,307
-3,313
-4% -$129K 0.03% 101
2023
Q1
$3.33M Buy
81,620
+651
+0.8% +$28.1K 0.04% 97
2022
Q4
$4.15M Sell
80,969
-54
-0.1% -$2.59K 0.05% 86
2022
Q3
$3.55M Sell
81,023
-22
-0% -$1.07K 0.05% 91
2022
Q2
$4.25M Buy
81,045
+1,706
+2% +$86.9K 0.05% 89
2022
Q1
$4.11M Sell
79,339
-377
-0.5% -$19.6K 0.04% 94
2021
Q4
$4.71M Hold
79,716
0.04% 92
2021
Q3
$3.43M Sell
79,716
-1,016
-1% -$45K 0.03% 97
2021
Q2
$3.16M Buy
80,732
+3,809
+5% +$148K 0.03% 103
2021
Q1
$2.79M Buy
76,923
+7,754
+11% +$275K 0.03% 105
2020
Q4
$2.55M Buy
69,169
+3,434
+5% +$126K 0.03% 106
2020
Q3
$2.29M Sell
65,735
-6,320
-9% -$222K 0.03% 106
2020
Q2
$2.23M Sell
72,055
-677
-0.9% -$23K 0.03% 107
2020
Q1
$2.25M Sell
72,732
-2,203
-3% -$75.1K 0.04% 98
2019
Q4
$2.79M Sell
74,935
-3,663
-5% -$130K 0.04% 100
2019
Q3
$2.68M Sell
78,598
-741
-0.9% -$26.9K 0.04% 103
2019
Q2
$3.26M Buy
79,339
+18,730
+31% +$744K 0.05% 99
2019
Q1
$2.44M Sell
60,609
-7,199
-11% -$288K 0.04% 110
2018
Q4
$2.81M Buy
67,808
+4,180
+7% +$174K 0.05% 105
2018
Q3
$2.66M Sell
63,628
-925
-1% -$35.6K 0.04% 110
2018
Q2
$2.22M Sell
64,553
-3,302
-5% -$113K 0.04% 114
2018
Q1
$2.29M Sell
67,855
-6,589
-9% -$227K 0.04% 118
2017
Q4
$2.56M Buy
74,444
+465
+0.6% +$15.9K 0.05% 113
2017
Q3
$2.51M Sell
73,979
-75
-0.1% -$2.41K 0.05% 111
2017
Q2
$2.33M Sell
74,054
-12,785
-15% -$403K 0.05% 110
2017
Q1
$2.82M Sell
86,839
-84
-0.1% -$2.65K 0.06% 108
2016
Q4
$2.68M Buy
86,923
+3,906
+5% +$119K 0.06% 108
2016
Q3
$2.67M Sell
83,017
-97
-0.1% -$3.24K 0.06% 110
2016
Q2
$2.78M Buy
83,114
+11,380
+16% +$363K 0.06% 109
2016
Q1
$2.02M Sell
71,734
-13,450
-16% -$384K 0.05% 115
2015
Q4
$2.61M Sell
85,184
-1,857
-2% -$58.4K 0.06% 108
2015
Q3
$2.77M Hold
87,041
0.07% 107
2015
Q2
$2.77M Sell
87,041
-1,978
-2% -$64.5K 0.07% 107
2015
Q1
$2.94M Sell
89,019
-611
-0.7% -$19.4K 0.07% 103
2014
Q4
$2.65M Buy
89,630
+1,652
+2% +$47.4K 0.07% 105
2014
Q3
$2.47M Buy
87,978
+1,001
+1% +$28.1K 0.07% 108
2014
Q2
$2.45M Buy
86,977
+14,962
+21% +$427K 0.07% 108
2014
Q1
$2.19M Buy
72,015
+445
+0.6% +$13.3K 0.06% 114
2013
Q4
$2.08M Buy
71,570
+10,402
+17% +$303K 0.06% 113
2013
Q3
$1.67M Sell
61,168
-4,827
-7% -$131K 0.05% 117
2013
Q2
$1.75M Buy
+65,995
New +$1.82M 0.05% 124

Other funds holding PFE

Loring Wolcott & Coolidge Fiduciary Advisors's PFE Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors reduced its Pfizer (PFE) stake by 7.2% in Q2 2026, selling an estimated $115K and leaving 56,816 shares worth $1.37M. The position accounts for 0.01% of the portfolio, ranked #150.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.71M in Q4 2021. 1,421 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Loring Wolcott & Coolidge Fiduciary Advisors held 56,816 shares of Pfizer worth $1.37M as of Q2 2026.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 4,395 Pfizer shares in Q2 2026, an estimated $115K.
  • Pfizer made up 0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #150 holding.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Pfizer position peaked at $4.71M in Q4 2021.
  • 1,421 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.